ASCO GI 2023 | Disparities and clinical relevance in NGS for NETs

Bahar Laderian, MD, Cleveland Clinic, Cleveland, OH, comments on disparities in the rates of next-generation sequencing (NGS) in patients with neuroendocrine tumors, where African-Americans are less likely to have their tumor profiled. Whilst RB1 and TP50 have been identified as genes that are associated with more aggressive tumors, RNA expression may be more effective in sequencing tumors. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.